Clinical trials: Ductus Arteriosus, Patent
Patent Ductus Arteriosus, Preterm
Precision Dosing of Oral Ibuprofen for PDA, A Pilot RCT
Newborns born early are at risk for a serious health problem called patent ductus arteriosus (PDA). PDA is a passageway between heart and lung that can cause life-threatening complications such as bleeding in the brain or even…
- Trial name
- MIPD-PDA (NCT07143201)
- Testing
- Standard Dose - Ibuprofen oral suspension, Precision Dose - Ibuprofen oral suspension
- Where
- Canada
- Volunteers
- 26 people
- Sponsor
- Hamilton Health Sciences Corporation
Patent, Ductus
Emergency/Compassionate Use - AMPLATZER Duct Occluder
Emergency/compassionate use for the AMPLATZER Duct Occluder
- Conditions
- Patent, Ductus, Arteriosus
- Trial name
- NCT00583583
- Testing
- Device closure with the AMPLATZER Duct Occluder
- Sponsor
- Abbott Medical Devices
Congenital Heart Defect, Patent Ductus Arteriosus
Effect of PDA Closure on the Left Ventricular Remodeling
failure of closure of the ductus arteriosus after birth results in a congenital anomaly known as patent ductus arteriosus. The large ductus can induce left side heart remodeling changes which could interfere with the normal…
- Trial name
- NCT04964531
- Testing
- speckle tracking echocardiography
- Volunteers
- 48 people
- Sponsor
- Ahmed Mohamed Moheb El-Din
Indomethacin Therapy, Patent Ductus Arteriosus
The Use of B-type Natriuretic Peptide (BNP) to Predict Closure of a Patent Ductus Arteriosus (PDA) in Premature Infants
A patent ductus arteriosus (PDA) is associated with increased morbidity in premature infants. Standard indomethacin treatment is associated with intestinal and renal morbidity.
- Trial name
- NCT00500305
- Testing
- Withhold standard INDO dose if BNP < 100 pg/ml
- Volunteers
- 60 people
- Sponsor
- University of Virginia
Persistent Ductus Arteriosus
Betamethasone and Closure of Ductus Arteriosus
The ductus arteriosus (DA) normally closes after birth as a result of exposure to oxygen. Its persistence of DA (PDA) occurs in 20 to 50% of very preterm infants and is associated with significant morbidity and mortality…
- Trial name
- CELESTE (NCT05987202)
- Testing
- DA closure in a population of premature infants
- Where
- France
- Volunteers
- 51 people
- Sponsor
- Hospices Civils de Lyon
Ductus Arteriosus, Patent
Percutaneous Intervention Versus Observational Trial of Arterial Ductus in Low Weight Infants
Patent Ductus Arteriosus is a developmental condition commonly observed among preterm infants. It is a condition where the opening between the two major blood vessels leading from the heart fail to close after birth.
- Trial name
- PIVOTAL (NCT05547165)
- Testing
- Percutaneous Patent Ductus Arteriosus Closure (PPC), Responsive Management Intervention, Echocardiogram, cardiac
- Where
- 24 sites in United States
- Volunteers
- 240 people
- Sponsor
- Nationwide Children's Hospital
Ductus Arteriosus
The Role of Fetal Ductus Arteriosus in Predicting Spontaneous Labour at Term
The exact mechanism stimulating the parturition in humans is still relatively unknown. Prostaglandins, by mediating cervical ripening and early stimulation of myometrial contractions, are likely to play a major role in the…
- Trial name
- NCT03073460
- Testing
- Ultrasound examination
- Sponsor
- Unity Health Toronto
Patent Ductus Arteriosus
Treatment of a PDA With Acetaminophen in Preterm Neonates: Exploring Various Indications
This study will evaluate the use of acetaminophen in preterm infants when a patent ductus arteriosus (PDA) is of concern. We will perform two simultaneous prospective observational studies over a 3 year period.
- Trial name
- NCT03289390
- Testing
- Acetaminophen
- Where
- United States
- Volunteers
- 11 people
- Sponsor
- Albany Medical College
Patent Ductus Arteriosus, Infant, Premature
Ibuprofen vs Expectant Management for hsPDA in Preterm Infants: Retrospective Cohort
This retrospective cohort study compares ibuprofen treatment versus expectant management for hemodynamically significant patent ductus arteriosus (hsPDA) in preterm infants.
- Trial name
- IMPACT-PDA (NCT07533721)
- Testing
- Ibuprofen
- Where
- China
- Volunteers
- 541 people
- Sponsor
- Shengjing Hospital
Patent Ductus Arteriosus, Congenital Heart Disease
PDA for Kidneys Study
The goal of this observational study is to gather more information on kidney oxygen levels in babies with a patent ductus arteriosus (PDA), and evaluate the relationships between kidney oxygen levels, PDA status and kidney…
- Trial name
- PDA4K (NCT06658496)
- Testing
- Near Infrared Spectroscopy
- Where
- United States
- Volunteers
- 27 people
- Sponsor
- University of Wisconsin, Madison
Patent Ductus Arteriosus, Extreme Prematurity
Canadian National PDA Treatment Study
Patent ductus arteriosus (PDA) is the most common cardiovascular problem that develops in preterm infants. Persistent PDA may result in higher rates of death, chronic lung disease (CLD), pulmonary hemorrhage, necrotizing…
- Trial name
- CANRxPDA (NCT04347720)
- Testing
- Indomethacin, Ibuprofen, Acetaminophen
- Where
- 22 sites in Canada
- Volunteers
- 1,663 people
- Sponsor
- IWK Health Centre
Apnea of Prematurity, Apneic Spells of Newborn Nos
Cardio-respiratory Events in Preterm Infants During Transition
Cardio-respiratory events (CRE), defined as intermittent episodes of hypoxemia and/or bradycardia, are particularly common among preterm infants.
- Conditions
- Apnea of Prematurity, Apneic Spells of Newborn Nos, Patent Ductus Arteriosus, Premature Birth
- Trial name
- NCT04123691
- Testing
- pulse oximetry monitoring
- Where
- Italy
- Volunteers
- 32 people
- Sponsor
- IRCCS Azienda Ospedaliero-Universitaria di Bologna
Prematurity; Extreme, Low Birthweight, Extremely (999 Grams or Less)
Extremely Low Gestatonal Age Infants' Paracetamol Study
In the present trial, early, intravenous paracetamol is compared to placebo in extremely premature or low birth weight infants in order to evaluate the effect on ductal closure.
- Trial name
- Paras (NCT03641209)
- Testing
- Paracetamol 10mg/mL infusion solution
- Where
- Finland
- Volunteers
- 40 people
- Sponsor
- Outi Aikio
Patent Ductus Arteriosus After Premature Birth
Paracetamol Versus Ibuprofen in Premature Infants With Hemodynamically Significant Patent Ductus Arteriosus
Multicentric, double-blind clinical trial, which will evaluate the efficacy of iv paracetamol versus standard treatment with ibuprofen in the closure of patent ductus arteriosus in the preterm newborn.
- Trial name
- IBUPAR (NCT04037514)
- Testing
- Paracetamol, Ibuprofen
- Where
- 4 sites in Spain
- Volunteers
- 133 people
- Sponsor
- Máximo Vento Torres
Patent Ductus Arteriosus
Post Marketing Clinical Follow Up Study to Evaluate Efficacy and Safety of the Occlutech PDA Occluder in Patients With Patent Ductus Arteriosus Defects
This retrospective and prospective, multicenter, international post marketing follow up study evaluates the safety and efficacy of the Occlutech® PDA Occluder, delivered using the Occlutech Occlusions Pusher (OOP), in subjects…
- Trial name
- NCT05264753
- Testing
- Occlutech® PDA Occluder
- Where
- 15 sites in Canada, France and 7 more
- Volunteers
- 255 people
- Sponsor
- Occlutech International AB
Prematurity, Respiratory Distress Syndrome
Curosurf and Survanta Treatment(CAST)of RDS in Very Premature Infants
Approval of surfactant by the FDA in 1989 for the treatment of Respiratory Distress Syndrome (RDS) in premature infants greatly improved survival rates.
- Conditions
- Prematurity, Respiratory Distress Syndrome, Patent Ductus Arteriosus
- Trial name
- CAST (NCT00767039)
- Testing
- Survanta (beractant), Curosurf (poractant)
- Where
- United States
- Volunteers
- 52 people
- Sponsor
- Alan Fujii
Patent Ductus Arteriosus
Paracetamol And Ibuprofen/Indomethacin in Closing Patent Ductus Arteriosus
The purpose of this pilot trial is to study efficacy and safety of simultaneous intravenous (iv) ibuprofen/indomethacin and paracetamol medications in the closure of patent ductus arteriosus (PDA) in preterm infants.
- Trial name
- PAI (NCT03648437)
- Testing
- Paracetamol 10Mg/mL, 0.45% Sodium Chloride, Ibuprofen
- Where
- 4 sites in Finland
- Volunteers
- 22 people
- Sponsor
- University of Oulu
Patent Ductus Arteriosus, Duct-dependent Cyanotic Congenital Heart Disease
Feasibility, Efficacy and Safety of IBS ® for Implantaiton in the PDA in Duct-dependent Cyanotic CHD
This is a pilot study on feasibility, efficacy and safety of IBS ® for implantation in the PDA in duct-dependent cyanotic CHD, and its objective is to investigate the feasibility, safety and efficacy of iron resorbable stent…
- Trial name
- NCT04291222
- Testing
- Iron biocorrodable coronary scaffold system
- Where
- Malaysia
- Volunteers
- 10 people
- Sponsor
- Lifetech Scientific (Shenzhen) Co., Ltd.
Patent Ductus Arteriosus
Serum Level Measurement of Oral Paracetamol and Oral Ibuprofen for Patent Ductus Arteriosus Treatment in Preterm Infants
The purpose of this study is to determine oral paracetamol and ibuprofen efficacy and safety in relation to serum levels in closure of patent ductus arteriosus in preterm infants.
- Trial name
- NCT01544972
- Testing
- Oral paracetamol, Oral ibuprofen
- Where
- Turkey (Türkiye)
- Volunteers
- 80 people
- Sponsor
- Zekai Tahir Burak Women's Health Research and Education Hospital
Patent Ductus Arteriosus in Preterm Infants
Comparison of Infusion Paracetamol Protocols in PDA
The aim of this study was to evaluate the effect of paracetamol on patent ductus arteriosus (PDA) closure and clinical outcomes in preterm infants when used as standard intermittent bolus and continuous intravenous (IV) infusion.
- Trial name
- NCT04469413
- Testing
- Paracetamol Infusion
- Where
- Turkey (Türkiye)
- Volunteers
- 138 people
- Sponsor
- Ankara University